Invicorp Injection 25mcg/2mg 5 x 0.35ml ampoules

£94.00

I will send you my prescription in the post.

I already have a prescription from my doctor and I will post it to you.

Prescription Only Medication
Injectable - suitable for patients who have used this type of injection before
Comes with all syringes and needles plus instructions for self-injection
Product should be kept in the fridge
Will be dispatched to you in a fridge pouch containg an ice-block inside a sturdy cardboard box which should be opened immediately upon receipt

Invicorp is a treatment for erectile dysfunction. It is supplied as ampoules for injection and each ampoule contains 25 micrograms of Aviptadil (vasoactive intestinal polypeptide) and 2 mg of Phentolamine mesilate.

Invicorp works by influencing the flow of blood in and out of the penis. Phentolamine mesylate increases the flow of blood into the penis, while aviptadil reduces the flow of blood from the penis. This causes more blood to stay in the penis thus forming an erection.

It will take a little time for you to obtain an erection after injecting the Invicorp – between five and 10 minutes. The erection will normally last no longer than an hour. Contact your doctor or a hospital if your erection has lasted for more than 4 hours.

Please read the enclosed leaflet carefully before using Invicorp.

It should only be used after obtaining a prescription from a UK registered doctor and you must not take any other medicines for erectile dysfunction at the same time as Invicorp.

Invicorp is intended for direct injection into the spongy tissue on either side of the shaft of the penis (intracavernous injection). A doctor or nurse will show you how to carry out the first injection and you must check the instructions in the patient information leaflet for information on preparing for the injection. If you cannot remember how to administer the injection, you should consult your doctor. You must not try to use the injection if you are unsure what to do.

The usual dose is the injection of one ampoule (25 micrograms of aviptadil (vasoactive intestinal polypeptide) and 2 mg of phentolamine mesilate). You must inject the whole of the contents of the ampoule each time the product is administered.

You must not administer more than one ampoule per day, and not exceed three injections per week. Each ampoule contains the correct amount for a single injection.

The active substances in Invicorp are contains 25 micrograms of aviptadil and 2 mg of phentolamine mesilate.. The other components are Sodium chloride, Disodium edetate, Phosphoric acid, Sodium hydroxide (for pH-adjustment), Hydrochloric acid (for pH-adjustment) Water for injections

Invicorp can cause side effects, although not everybody experiences them.

Serious side effects

Rare side effects (expected in 1 to 10 out of 10,000 patients)

Long lasting painful erection. Contact your doctor or a hospital if your erection has lasted for more than 4 hours.

Very rare side effects (expected in less than 1 out of 10,000 patients)

Heart Cramps (angina), chest pain. Contact your doctor or a hospital.
Heart thrombus with shortness of breath, anxiety, possible severe pain radiating into left arm and chest pain. Call 999 if these symptoms arise.

Non serious side effects

Common side effects (expected in 1 to 10 out of 100 patients)

Flushing of the face and upper part of the body.
Bruising around the injection site. You can lower the risk of bruising by avoiding injecting Invicorp into a visible vein.

Uncommon side effects (expected in 1 to 10 out of 1,000 patients)

Headache, dizziness.
Increased heart rate or palpitations.

Stop using Invicorp if you get some of these side effects.

Accumulation of blood under the skin at the injection site.

Rare side effects (expected in 1 to 10 out of 10,000 patients)

Small lumps on the penis caused by repeated injections.
Pain at the injection site.

For a full list of potential side effects and other important information, please read the patient leaflet provided in the pack before starting any course of treatment.

Authored by Robert Bradshaw on 13 November 2020. Reviewed by Stuart Gale on 13 November 2020.